First Biologic for Ulcerative Colitis: Gut-Selective Safety or Faster Control
A single patient starting her first biologic for moderate ulcerative colitis, weighing vedolizumab's gut-selective safety profile against anti-TNF therapy's faster onset of action.
Helen O., a 61-year-old woman and retired librarian, has managed her moderate ulcerative colitis on mesalamine for four years, well enough to keep leading her weekly book club, until a flare over the past two months left her with five to six loose stools a day and enough abdominal cramping that she skipped last month's meeting for the first time since it started. She has type 2 diabetes controlled on metformin, hypertension on lisinopril, and a psoriasis history well-managed by topical therapy for over a decade — unremarkable by itself, but relevant to the choice in front of her now that mesalamine has stopped being enough and a biologic is the actual next step.
Both vedolizumab and adalimumab are approved first-line options for her, and unusually for a biologic choice, they have been compared directly. VARSITY (Sands et al., NEJM 2019) randomized 769 patients with moderate-to-severe ulcerative colitis to one or the other and found vedolizumab superior at week 52 for clinical remission (31.3% vs 22.5%) and for endoscopic improvement (39.7% vs 27.7%). Helen is inside that population — moderate-to-severe disease, no prior adalimumab, which was VARSITY's own exclusion — so the colitis question is less open than a first-biologic choice usually is. What VARSITY measured, though, was colitis, and Helen's chart carries a second disease it never looked at. Vedolizumab's gut selectivity — it blocks the alpha-4-beta-7 integrin that traffics lymphocytes specifically into intestinal tissue, largely sparing systemic immune surveillance — carries its own appeal in a 61-year-old already carrying diabetes and hypertension. The cost is speed: in VARSITY the two arms separated late rather than early, the week-14 difference not significant and vedolizumab's advantage only clear by week 52, which is a real cost for a woman whose flare is two months old and eating into her weeks now.
Adalimumab's own pull here isn't just speed. It's the one drug on the table that would also treat a second condition she actually carries, and the calculus around that depends less on ulcerative colitis trial data than on how her psoriasis has behaved on its own: quiet for over a decade on topical therapy alone, not escalating, not something she has mentioned to her gastroenterologist unprompted at any of her last several visits. That history is the actual variable the group has to read correctly — a dual-benefit argument is only as strong as how active the second disease really is right now, not how real the diagnosis is on paper.
Clinic, choosing her first biologic
I'd start vedolizumab, and I'd lead with the head-to-head rather than the mechanism, because we rarely get one. VARSITY compared these two drugs directly in moderate-to-severe UC and vedolizumab won on both clinical remission and endoscopic improvement at week 52. Her disease is moderate, not severe — no hospitalization pressure, no urgent need for the fastest possible response — so the late separation VARSITY showed is a cost she can afford. And the gut selectivity is worth weighting more heavily in a 61-year-old carrying diabetes and hypertension than it would be in someone younger.
I'd flag her psoriasis history before this goes further. It's well-controlled now, but adalimumab actually treats psoriatic disease directly — it's approved for psoriasis and psoriatic arthritis in its own right — while vedolizumab has no such benefit and, more specifically, carries case reports of new-onset or worsening psoriasiform reactions in patients started on it. If her skin disease were more active I'd call this close to decisive rather than just a consideration.
Both of you are naming real, genuinely competing considerations, and I don't think the cardiovascular argument and the dermatologic one actually point the same direction here, which is the honest reason this isn't a clean call. Her psoriasis has been quiet for over a decade on topical therapy alone — it isn't the active, disabling disease adalimumab's dual benefit would most clearly justify choosing around. Her diabetes and hypertension, by contrast, are active, present-tense findings on today's chart, not a decade-old quiet history. Weighing an active cardiometabolic profile against a quiescent skin condition — and with VARSITY already favoring vedolizumab on the disease we are actually treating — gut selectivity is doing more real work for her right now than adalimumab's dermatologic upside would be. I'd start vedolizumab, with an explicit six-week check-in given the onset-speed tradeoff — if she isn't showing meaningful improvement by then, that's the point to reconsider rather than waiting the full GEMINI timeline on faith.
Agreed: vedolizumab induction, mesalamine continued, and an explicit six-week clinical check-in rather than waiting for a standard follow-up interval, given that vedolizumab's own trial data show a real share of eventual responders hadn't met response criteria that early. The rheumatologist's psoriasis concern is documented in the chart as a factor to revisit if her skin disease becomes active again, not as something the current plan overrides permanently.